Watch ARQT. Know when insiders buy.
One email the day a filing lands. Free.
Work order
21
FLAG · insiders 26, shorts 15
Insiders, 90 days
−$1M
net selling · 0 buys, 4 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $3BP/E 113.8DIV YIELD —FCF YIELD 1.30%REV TTM $464M +76.1%NET INCOME $28.5MNET DEBT $74.8M52W 16.73 – 31.20NEXT EARNINGS Oct 27SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $129.9M | +59.3% | 91.6% | $16.4M | $15M | — | 0.11 | $12.6M | $158K | $12.5M | Aug 5 |
| Q1 2026 · Mar 31 | $105.4M | +60.1% | 90.7% | −$9.1M | −$11.3M | — | -0.09 | $2.2M | $0 | $2.2M | Aug 5 |
| Q4 2025 · Dec 31derived | $129.5M | +81.5% | 91.0% | $18.4M | $17.4M | — | 0.13 | $26.2M | $0 | $26.2M | Feb 25 |
| Q3 2025 · Sep 30 | $99.2M | +121.7% | 91.2% | $8.5M | $7.4M | — | 0.06 | −$1.8M | $0 | −$1.8M | Oct 28 |
| Q2 2025 · Jun 30 | $81.5M | +164.1% | 90.8% | −$14.6M | −$15.9M | — | -0.13 | $324K | $78K | $246K | Aug 5 |
| Q1 2025 · Mar 31 | $65.8M | +32.8% | 86.6% | −$24.5M | −$25.1M | — | -0.20 | −$30.4M | $608K | −$31M | Aug 5 |
| Q4 2024 · Dec 31derived | $71.4M | +427.6% | 90.3% | −$7.6M | −$10.8M | — | -0.08 | −$748K | $0 | −$748K | Feb 25 |
| Q3 2024 · Sep 30 | $44.8M | +17.4% | 87.7% | −$39.1M | −$41.5M | — | -0.33 | −$34.7M | $143K | −$34.8M | Oct 28 |
| Q2 2024 · Jun 30 | $30.9M | — | 88.8% | −$50.1M | −$52.3M | — | -0.42 | −$45.1M | $0 | −$45.1M | Oct 28 |
| Q1 2024 · Mar 31 | $49.6M | — | 93.4% | −$31.6M | −$35.4M | — | -0.32 | −$31.6M | $0 | −$31.6M | Oct 28 |
| Q4 2023 · Dec 31derived | $13.5M | — | 83.4% | −$61.2M | −$66.3M | — | -0.59 | −$56.2M | $6K | −$56.3M | Feb 25 |
| Q3 2023 · Sep 30 | $38.1M | — | 96.9% | −$36.9M | −$44.8M | — | -0.73 | −$44M | $64K | −$44M | Nov 6 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $376.1M | 90.2% | −$12.2M | −$16.1M | -4.3% | -0.13 | −$5.6M | $686K | −$6.3M | — | — |
| FY2024 · to Dec 31 | $196.5M | 90.3% | −$128.4M | −$140M | -71.3% | -1.16 | −$112.2M | $143K | −$112.3M | — | — |
| FY2023 · to Dec 31 | $59.6M | 91.6% | −$241.1M | −$262.1M | -439.8% | -3.78 | −$247.1M | $428K | −$247.5M | — | — |
| FY2022 · to Dec 31 | $3.7M | 79.5% | −$301.6M | −$311.5M | -8449.8% | -5.66 | −$257.7M | $333K | −$258M | — | — |
| FY2021 · to Dec 31 | — | — | −$206.5M | −$206.4M | — | -4.18 | −$174.6M | $995K | −$175.6M | — | — |
| FY2020 · to Dec 31 | — | — | −$136.6M | −$135.7M | — | -3.80 | −$113M | $321K | −$113.4M | — | — |
Every number comes from Arcutis Biotherapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.